Original language | English (US) |
---|---|
Pages (from-to) | 13-21 |
Number of pages | 9 |
Journal | Clinical Trials |
Volume | 9 |
Issue number | 1 |
DOIs |
|
State | Published - Feb 2012 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Clinical Trials, Vol. 9, No. 1, 02.2012, p. 13-21.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Panel discussion 1
AU - Schwartz, Sandy
AU - Lauer, Michael
AU - McNeil, Barbara
AU - Tunis, Sean
AU - Diamond, Guy
AU - Silber, Jeff
AU - Herzig, Abbe
AU - Lauer, Mike
AU - Temple, Bob
AU - Lee, Jack
AU - Rhodes, Karen
AU - Morton, Sally
AU - Rotelli, Matthew
N1 - Funding Information: Michael Lauer: We normally think of the National Institutes of Health (NIH) as a funding agency, but one of our major functions is also to promote thinking, and I often tell my colleagues how enjoyable it is to work at a think tank. This particular conference is funded by an NIH R13 grant, and I have to say, what an incredible pleasure it is to see our money going to an event like this where every single seat in this room is taken by very thoughtful, creative eople. I want to congratulate you for putting on a terrific conference. The first two talks were really fabulous to get this thing started. Dr Morton talked about the need for early successes, and I think if there is one thing to encourage us about CER is that all is not bad. We have had a number of major successes, which should spur us to take this whole field to a much higher level. When I was a resident, the management for acute ST segment elevation myocardial infarction was lidocaine and nitrates. We now know that with lidocaine, we were probably killing people and with nitrates we were giving our patients horrible headaches. The management now is completely different. In 1985, there was a major pragmatic trial that was published out of Italy called GISSI. This was a trial of 20,000 people, and it was simple. The investigators enrolled patients who came to the emergency room for whom the doctor thought the patient was having a heart attack. The patient was randomized to get streptokinase or nothing and that was it. The trial was that simple and over 30 days, the death rate was noted to be markedly reduced. Now since then, this field has dramatically improved, and the outcomes for patients with ST segment elevation myocardial infarction are much, much better than they were, back in the 1980s, the reason: randomized trials. We’ve had other major successes: atrial fibrillation, hypertension, and hypercholesterolemia. Much of cardiovascular medicine has dramatically changed, and we have seen dramatic improvement in outcomes, still far from perfect but largely because of the successes of large-scale randomized trials.
PY - 2012/2
Y1 - 2012/2
UR - http://www.scopus.com/inward/record.url?scp=84863127948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863127948&partnerID=8YFLogxK
U2 - 10.1177/1740774511433047
DO - 10.1177/1740774511433047
M3 - Comment/debate
C2 - 22334464
AN - SCOPUS:84863127948
SN - 1740-7745
VL - 9
SP - 13
EP - 21
JO - Clinical Trials
JF - Clinical Trials
IS - 1
ER -